Pevion Fact Sheet Ju.. - Pevion Biotech AG
Pevion Fact Sheet Ju.. - Pevion Biotech AG
Pevion Fact Sheet Ju.. - Pevion Biotech AG
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Management Team<br />
Evert Kueppers CEO<br />
Christian Spyr Head of Clinical<br />
Development &<br />
Project Management<br />
Mario Amacker Head of Process<br />
Development &<br />
Manufacturing<br />
Christian Moser Head of Research<br />
Board of Directors<br />
Didier Hoch Chairman,<br />
Ex- Chairman of<br />
Sanofi Pasteur MSD<br />
Jean-Paul Prieels Ex-Senior VP R&D of<br />
GSK Biologicals<br />
Achim Kaufhold CMO Basilea<br />
Pharmaceutica<br />
Daniel Richner BZ Fund Managemt<br />
Daniel Erne CTO Bachem Hold<br />
Klaus Breiner BB <strong>Biotech</strong> Ventures<br />
<strong>Pevion</strong> <strong>Biotech</strong> <strong>AG</strong><br />
Worblentalstrasse 32<br />
3063 Ittigen<br />
Switzerland<br />
Phone +41 31 550 44 44<br />
Fax +41 31 550 44 45<br />
info@pevion.com<br />
www.pevion.com<br />
R E C E N T M I L E S T O N E S<br />
PEV7 therapeutic RVVC vaccine achieved positive Phase I interim results<br />
PEV4 RSV vaccine achieved preclinical proof-of-concept in two animal<br />
models: Mice and Cotton rats were protected against a live virus challenge,<br />
no pathological events were detected<br />
Licensee Mymetics announced positive Phase I trial results with virosomebased<br />
HIV vaccine<br />
Development of a mucosal galenic, freeze-dried version of virosomes<br />
enabling among others vaginal capsule formulation<br />
New Chairman with relevant vaccine development / launch experience<br />
New Board member with portfolio and vaccine development experience<br />
Strengthened management with experienced vaccine development<br />
specialist and biotech-proven CEO<br />
Additional CHF 10 million funding<br />
Partnership with US vaccine company<br />
S T R O N G T R A C K R E C O R D<br />
<strong>Pevion</strong>’s track record to date proves the company’s capability to translate its<br />
assets into successful product development and to generate added value for<br />
its shareholders.<br />
Products developed and manufactured by <strong>Pevion</strong> were tested in a total of 7<br />
Phase I and Phase II trials<br />
To date, 4 products demonstrated immunogenicity in human; 5 peptide<br />
and 2 protein antigens validated<br />
Excellent safety and tolerability in human, no failure ever<br />
PEV3 Malaria vaccine successfully out-licensed after Phase II<br />
Technology and product design out-licensed for HIV vaccine; now<br />
successful in clinical Phase I<br />
11x patent families, in-depth know how and trade secrets<br />
Platform improvements & new IP (freeze-dried formulation, mucosal<br />
galenic, immunostimulation)<br />
GMP compliance status granted by Swissmedic<br />
F I N A N C I A L S U M M A R Y<br />
<strong>Pevion</strong> was founded in 2002 by Bachem Holding and Berna <strong>Biotech</strong>, which<br />
provided a total of CHF 20 million as a start- up capital. Berna <strong>Biotech</strong> was<br />
acquired by Crucell N.V. (now a Johnson & Johnson subsidiary) in 2006. In<br />
August 2007, the Company closed a CHF 15 million series A financing round<br />
with new investors BZ Bank Aktiengesellschaft, BB <strong>Biotech</strong> Ventures and Core<br />
Capital Partners as well as the existing investor Bachem <strong>AG</strong>. Crucell was<br />
bought out in November 2007. In September 2010, <strong>Pevion</strong> secured additional<br />
CHF 10 million in financing from its current investors.<br />
C O N T A C T<br />
To request further information, please contact:<br />
<strong>Ju</strong>lian Wagner, PhD, Business Development<br />
info@pevion.com, Tel: +41 31 550 44 44